AMG0001-JN-103 study

A Phase 3 study of AMG0001 in Fontaine grade III patients for PAD

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT1080224997

Enrollment

Registered

2019-12-24

Start date

2019-12-25

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cronic arterial obstruction

Interventions

investigational material(s) Generic name etc : Beperminogene Perplasmid INN of investigational material : beperminogen perplasmid Therapeutic category code : 49- Other agents affecting cellular functi

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Informed Cosent/The indication of revascularizationis difficult/Fontaine 3/No improvement of symptoms in the treated leg even after the existing medical treatment or procedures

Exclusion criteria

Exclusion criteria: less than 20 years old/ over 85 years old

Design outcomes

Primary

Measure	Time frame
efficacy confirmatory hemodynamic parameter, QOL, VAS	—

Secondary

Measure	Time frame
safety efficacy hemodynamic parameter, QOL,VAS	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026